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Abstract
Background—Gabapentinoid use for cancer-pain control may be problematic, given unclear 
mechanisms of action and increased concerns for physical dependence. The purpose of this report 
is to examine trends of gabapentinoid use among US adults with cancer from 2005–2015.
Methods—We conducted a serial, cross-sectional study using data from the Medical Expenditure 
Panel Survey (MEPS). We performed multiple logistic regression to examine the annual 
percentages of gabapentinoid users, which were adjusted for age, sex, and US region of residence.
Results—The amount of gabapentinoid prescriptions filled in 2015 was also estimated. The 
adjusted percentage of gabapentinoid users in 2015 was 5.60% (3.79%, 7.41%), 2.39 times greater 
than the percentage in 2005 (p < .001). By 2015, the number of gabapentinoid prescriptions had 
grown to approximately 3.52 million (2.40 million, 4.65 million).
Conclusion—We observed greater than a two-fold increase in the trend of gabapentinoid 
medication use among US adults with cancer. Investigations on the long-term efficacy of 
gabapentinoids for complex pain syndromes, and mitigation of risks, is essential to guide informed 
clinical management and keep patients safe.
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Patients with cancer often present with complex pain syndromes that vary in etiology. The 
estimated prevalence of chronic pain in patients undergoing primary cancer treatment, 
without advanced disease, ranges from 33–59%.1 First-line pain treatment with opioids has 
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varied effectiveness and faces additional scrutiny amidst the opioid crisis.2,3 Moreover, 
clinicians are prescribing alternative treatments to manage complex cancer pain.4 The drugs 
gabapentin and pregabalin (i.e., gabapentinoids) were developed originally for 
anticonvulsant therapy, but demonstrate efficacy for treating neuropathic pain and other 
chronic pain syndromes.5,6 Gabapentinoid use for cancer-pain syndromes may be 
problematic, given unclear mechanisms of action for pain control and concerns for physical 
dependence.7 The purpose of this report is to examine trends of gabapentinoid medications 
among US adults with cancer from 2005–2015.
We conducted a serial, cross-sectional study using data from the Medical Expenditure Panel 
Survey (MEPS). The sampling frame of the MEPS was non-institutionalized US adults (age 
18 and older), therefore excluding adults in medical facilities, inmates, and those serving in 
the armed forces. The survey collection procedures of the MEPS have been described 
elsewhere.8
Individuals with a cancer diagnosis in the MEPS, which was self-reported, were included for 
analysis. Using previously validated approaches, we used the MEPS prescription medication 
data files to identify adults who received a gabapentinoid.9 Users of a gabapentinoid were 
identified by with National Drug Code (NDC) classifications for “gabapentin” or 
“pregabalin.”
The MEPS allowed for complex survey design methods to adjust for the probability of 
selection, clustering of observations, and multiple stages of selection to yield national 
estimates.8 We examined the crude percentage of US adults with cancer who used a 
gabapentinoid from 2005–2015. Next, we used multiple logistic regression to examine the 
annual adjusted percentages of users of a gabapentinoid from 2005–2015, adjusting for age, 
sex, and US region of residence. The amount of gabapentinoid prescriptions filled in 2005, 
2010, and 2015 was also estimated with complex survey design. All analyses were 
performed with Stata, version SE 15 (StataCorp, LLC).
We observed that the crude percentages of adults with cancer who used a gabapentinoid in 
2005 and 2015 were approximately 3.28% (95% Confidence Interval: 2.10%, 4.23%) and 
8.26% (6.98%, 9.84%), respectively (p < .01). See Supplemental Table 1. By 2015, the crude 
percentages of adults who used a gabapentinoid increased across all age, sex, and US region 
of residence groups.
In 2015, the crude percentages of females with cancer who used a gabapentinoid was greater 
than the percentage of males, [8.86% (6.97%, 11.4%) and 7.54% (5.46%, 10.2%)]. The 
percentage of adults with cancer who used a gabapentinoid was the greatest in the 18–44 age 
group, 15.3% (9.59%, 24.6%), compared to adults age 45–64 and 65–85. The Southern US 
region had the highest percentage of adults with cancer who used a gabapentinoid, 11.1% 
(8.73%, 14.1%). The greatest increase in the percentage who used a gabapentinoid from 
2005 to 2015 occurred in adults residing in the West, 1.56% (0.45%, 5.02%) to 7.91% 
(5.85%, 10.7%), respectively (p = .11).
We found that the age-, sex-, and US region-adjusted percentage of adults who used a 
gabapentinoid in 2015 was 5.60% (3.79%, 7.41%), whereas the adjusted percentage in 2005 
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was 2.34% (1.28%, 3.40%; rate ratio 2.39; p < .001). See Figure 1. Additionally, the 
adjusted percentages in 2013 and 2014, surpassed 5%, [6.52% (4.60%, 8.45%); 6.18% 
(4.35%, 8.01%), respectively].
In 2005, the total number of gabapentinoid prescriptions filled among US adults with cancer 
was approximately 1.19 million (0.61 million, 1.78 million). By 2015, the number of 
gabapentinoid prescriptions had grown to approximately 3.52 million (2.40 million, 4.65 
million), an estimated increase of 0.46 million annually (95% CI 0.22 million, 0.70 million; 
p < .01 for monotonic trend).
Amidst an opioid epidemic, the observed upward pattern of gabapentinoid use may reflect 
public recognition of unwanted consequences of long-term opioid use.10. Yan and 
colleagues suggested that multiple well-designed clinical trials of gabapentin for reduced 
pain and analgesic use following various surgical procedures demonstrated efficacy, but the 
evidence of efficacy is less clear in cancer-pain syndromes.11 We were surprised to find the 
crude percentage of adults who used a gabapentinoid in the 18–44 age group was much 
greater than the other age groups, which may indicate that clinicians perceive gabapentinoids 
as a prominent non-opioid therapy among younger adults diagnosed with cancer.
Additionally, the increased use of gabapentinoids may reflect the growing incidence of 
chemotherapy-induced neuropathic pain in cancer survivors.12,13 Gabapentinoid prescribing 
for chronic, non-cancer pain conditions has risen dramatically since 2012.14 Significant late 
effects of chemotherapy-induced neuropathic pain may persist from two to five years 
following the first course of neurotoxic chemotherapy, which necessitates long-term 
prescription of analgesic therapy.13
To our knowledge, this is the first evidence of a consistent, upward trend of gabapentinoid 
medication use among adults with cancer in the US. Evidence from Johansen observed a 
smaller percentage of gabapentinoid users in the general US adult (age > 17) population, 
although a nearly threefold increase was observed from 2002–2015.15 Gabapentinoid use for 
cancer pain is off label with conflicting evidence for benefit.6 A deeper understanding of 
dosages, drug interactions, and adverse effects of gabapentinoid therapies would provide 
clinicians with needed data to personalize pain management. In addition to physical 
dependence, gabapentinoids increase respiratory depression risks in patients who are opioid 
tolerant or who receive it in the post-operative setting.16,17 Gabapentinoids in combination 
with opioids increases overall mortality compared to either drug alone.18,19
There are several study limitations. First, the indications of medication use for MEPS 
participants were unknown. Therefore, we could not determine if gabapentinoids were used 
for cancer-pain syndromes or anticonvulsant therapy. However, gabapentin and pregabalin 
are not considered first-line therapies for seizures or epilepsy.20 Second, the MEPS data 
include self-reported measures, which limits our ability to identify errant reporting. Finally, 
the analyses were limited to outpatient prescription medications only, which may not fully 
represent the trends of inpatient, unprescribed, or unfilled medications used. Despite these 
limitations, to our knowledge this was the first study to examine trends over recent time in 
the use of gabapentinoids among adults with cancer in the US.
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Over time, we observed greater than a twofold increase in crude and adjusted percentages of 
adults with cancer who used a gabapentinoid medication. In recent years, adults with cancer 
are more likely to use a gabapentinoid. Investigations on the long-term efficacy of 
gabapentinoids for complex pain syndromes, and mitigation of risks, is essential to guide 
informed clinical management and keep patients safe.
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Figure 1. 
Trend in percentage of US adults with cancer who used a gabapentinoid medication with 
95% confidence intervals, adjusted for age, sex, and US region, 2005–2015.
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